NASDAQ:VAXX Vaxxinity (VAXX) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free VAXX Stock Alerts $0.12 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.11▼$0.1350-Day Range$0.12▼$0.8652-Week Range$0.11▼$3.10Volume1.97 million shsAverage Volume601,460 shsMarket Capitalization$14.78 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Vaxxinity alerts: Email Address Vaxxinity MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside5,903.4% Upside$7.00 Price TargetShort InterestBearish9.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.42) to ($0.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.20 out of 5 starsMedical Sector515th out of 908 stocksPharmaceutical Preparations Industry234th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingVaxxinity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxxinity has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.31% of the float of Vaxxinity has been sold short.Short Interest Ratio / Days to CoverVaxxinity has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Vaxxinity has recently increased by 3.43%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVaxxinity does not currently pay a dividend.Dividend GrowthVaxxinity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VAXX. Previous Next 2.2 News and Social Media Coverage News SentimentVaxxinity has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Vaxxinity this week, compared to 0 articles on an average week.Search Interest17 people have searched for VAXX on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.MarketBeat Follows4 people have added Vaxxinity to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxxinity insiders have not sold or bought any company stock.Percentage Held by Insiders59.07% of the stock of Vaxxinity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.95% of the stock of Vaxxinity is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vaxxinity are expected to grow in the coming year, from ($0.42) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxxinity is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxxinity is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxxinity has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Vaxxinity Stock (NASDAQ:VAXX)Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.Read More VAXX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VAXX Stock News HeadlinesApril 22, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Down 58% Today?April 19, 2024 | marketwatch.comVaxxinity Plans to Delist Shares From NasdaqApril 27, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 19, 2024 | globenewswire.comVaxxinity Issues Shareholder LetterApril 19, 2024 | globenewswire.comVaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockMarch 28, 2024 | globenewswire.comVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual MeetingMarch 27, 2024 | investorplace.comVAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023March 27, 2024 | globenewswire.comVaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdatesApril 27, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 7, 2024 | globenewswire.comVaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024February 15, 2024 | finance.yahoo.comVaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol LevelsFebruary 15, 2024 | finance.yahoo.comVaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 15, 2024 | globenewswire.comVaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 13, 2024 | finance.yahoo.comVaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024January 30, 2024 | finance.yahoo.comVaxxinity, UF Join Forces Against Neurodegenerative DiseasesJanuary 30, 2024 | finance.yahoo.comVaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of FloridaJanuary 19, 2024 | finance.yahoo.comVaxxinity & UCF to Collaborate on Space Medicine ResearchJanuary 18, 2024 | finance.yahoo.comVaxxinity Announces Collaboration on Space Medicine Research with University of Central FloridaJanuary 3, 2024 | finance.yahoo.comVaxxinity to Present at the 2024 J.P. Morgan Healthcare ConferenceDecember 12, 2023 | finance.yahoo.comThe Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and VaxxinityNovember 21, 2023 | markets.businessinsider.comAlzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And OthersNovember 20, 2023 | foxnews.comSeveral Alzheimer's vaccines enter clinical trials amid breakthrough treatments' successNovember 20, 2023 | msn.comResearchers return to Alzheimer's vaccines, buoyed by recent drug successNovember 13, 2023 | finance.yahoo.comVaxxinity to Present at Upcoming November Medical and Investor ConferencesNovember 8, 2023 | finance.yahoo.comVaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 10, 2023 | finance.yahoo.comPrivate companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap declineSeptember 7, 2023 | finance.yahoo.comDown -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX)See More Headlines Receive VAXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today4/26/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VAXX CUSIPN/A CIK1851657 Webwww.vaxxinity.com Phone254-244-5739FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+5,903.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-192.58% Return on Assets-88.04% Debt Debt-to-Equity Ratio0.99 Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual Sales$70,000.00 Price / Sales211.13 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book1.06Miscellaneous Outstanding Shares126,750,000Free Float51,878,000Market Cap$14.78 million OptionableNot Optionable Beta2.39 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Louis Garfield Reese IV (Age 42)Co-Founder & Executive Chairman of the Board Comp: $83.28kMs. Mei Mei Hu J.D. (Age 41)CEO & Director Comp: $551.73kMr. Jason Pesile CPA (Age 51)M.B.A., Chief Accounting Officer Dr. Jean-Cosme Dodart Ph.D.Chief Scientific OfficerMs. Sumita Ray J.D. (Age 50)Chief Legal & Administrative Officer Mr. Jon HarrisonChief Government OfficerMr. Mark Joinnides MSEChief of StaffMs. Amy B. Fix M.B.A.M.S., R.A.C., Head of RegulatoryMore ExecutivesKey CompetitorsLipocineNASDAQ:LPCNUnity BiotechnologyNASDAQ:UBXSensei BiotherapeuticsNASDAQ:SNSEEyenoviaNASDAQ:EYENIterum TherapeuticsNASDAQ:ITRMView All CompetitorsInsiders & InstitutionsIeq Capital LLCBought 83,262 shares on 2/7/2024Ownership: 0.066%Movers Lab Fund I Lp PrimeSold 25,089 sharesTotal: $41,898.63 ($1.67/share)Movers Lab Fund I Lp PrimeSold 5,308 sharesTotal: $9,979.04 ($1.88/share)View All Insider TransactionsView All Institutional Transactions VAXX Stock Analysis - Frequently Asked Questions Should I buy or sell Vaxxinity stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxxinity in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" VAXX shares. View VAXX analyst ratings or view top-rated stocks. What is Vaxxinity's stock price target for 2024? 1 brokerages have issued 1-year price objectives for Vaxxinity's stock. Their VAXX share price targets range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 5,903.4% from the stock's current price. View analysts price targets for VAXX or view top-rated stocks among Wall Street analysts. How have VAXX shares performed in 2024? Vaxxinity's stock was trading at $0.85 at the beginning of 2024. Since then, VAXX stock has decreased by 86.3% and is now trading at $0.1166. View the best growth stocks for 2024 here. When is Vaxxinity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our VAXX earnings forecast. How were Vaxxinity's earnings last quarter? Vaxxinity, Inc. (NASDAQ:VAXX) announced its quarterly earnings data on Wednesday, March, 27th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04. When did Vaxxinity IPO? Vaxxinity (VAXX) raised $90 million in an IPO on Thursday, November 11th 2021. The company issued 6,000,000 shares at $14.00-$16.00 per share. How do I buy shares of Vaxxinity? Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VAXX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
